Abstract: An optical device which maintains luminance characteristics to the greatest extent, improves light-collecting effects, and realizes a wide viewing angle, and a backlight unit and an LCD including the same. The optical device includes a light-transmitting base film. A plurality of convex portions is formed on at least one surface of the base film, and microscopic optical patterns have peaks and valleys, which abut each other, on part of the convex portions. Alternatively, a plurality of third fine optical patterns is formed on at least one surface of the base film. A portion of each third fine optical patterns abutting the base film forms a figure having long and short axes. Each of the third fine optical patterns has a peak with a height that decreases from the center to both ends thereof along the long axis.

Abstract: The present invention relates to a compound of the following formula 1, pharmaceutically acceptable salt and isomer thereof effective as agonist of melanocortin receptor, and an agonistic composition of melanocortin receptor comprising the same as active ingredient.

Abstract: The present invention provides stabilized antioxidant particles, each of which includes a core consisting of an antioxidant and a first coating layer formed on the surface of the core, wherein the first coating layer is formed by polymerizing at least one ?-lipoic acid or its derivative, a composition including the same, and a method for preparing the same.

Abstract: The present invention relates to a compound of the following formula 1, pharmaceutically acceptable salt and isomer thereof effective as agonist of melanocortin receptor, and an agonistic composition of melanocortin receptor comprising the same as active ingredient.

Abstract: The present invention elates to a process for preparing paclitaxel represented by formula (1) characterized in that: (a) an oxazolidine derivative represented by formula (2) or its salt in which X represents halogen, is coupled with a 7-trihaloacetyl-baccatin III represented by formula (3) in which R.sub.1 represents trihaloacetyl, in a solvent in the presence of a condensing agent to produce an oxazolidine substituent-containing taxane represented by formula (4) in which X and R.sub.1 are each as previously defined; (b) the oxazolidine ring is opened in a solvent in the presence of an acid, and the product thus obtained is reacted with benzoyl chloride in the presence of a base to produce a protected paclitaxel wherein the hydroxy group at 7-position is protected with trihaloacetyl group represented by formula (5) in which R.sub.1 is as previously defined; (c) then the protecting group at 7-position is removed by ammonia or a salt of ammonia with a weak acid in a solvent.